The FDA just picked its first company to sell an unauthorised device to Medicare patients
The US Food and Drug Administration named Dexcom as the first manufacturer selected for its Technology-Enabled Meaningful Patient Outcomes pilot on Tuesday. The programme, known as TEMPO, allows digital health devices to be offered to Medicare patients before the agency has authorised them for that use. The mechanism is enforcement discretion. Rather than granting approval, the FDA […] This story continues at The Next Web
Record details
Published: 27 July 2026
Source: The Next Web AI
Category: News
Topics: Healthcare
Retrieved: 28 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
NHS England admits its paperwork hid that Palantir staff can see identifiable patient data
The Next Web AI · 30 July 2026
Meta sued by 26 employees who say its AI systems targeted workers on medical leave for layoffs
The Next Web AI · 14 July 2026
Orange is building a €3bn French data centre business, funded from New Zealand
The Next Web AI · 27 July 2026
Jeff Bezos says stress is a signal to work harder, not a reason to stop
The Next Web AI · 26 July 2026
China fines Trip.com $765 million for forcing hotels into exclusive deals and controlling their prices
The Next Web AI · 25 July 2026
Modi breaks Instagram’s Reel record with 300 million views as student protests sweep India
The Next Web AI · 25 July 2026
How to cite this record
ethics.ai (27 July 2026), “The FDA just picked its first company to sell an unauthorised device to Medicare patients,” evidence record 13925, https://ethics.ai/record/13925 (originally published by The Next Web AI).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.